Covered recipient · General Payments record
AMY E BEDSOLE
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$417.99
- Reported across 24 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $295.51 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $93.52 | 6 |
| Amgen Inc. | $50.65 | 3 |
| Lilly USA, LLC | $50.40 | 3 |
| ABBVIE INC. | $31.01 | 2 |
| DEXCOM, INC. | $23.64 | 1 |
| Acerta Pharma LLC | $18.22 | 1 |
| iRhythm Technologies, Inc. | $15.00 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $13.07 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.43 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103299406 | CMS |
| ABBVIE INC. | $16.58 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103299408 | CMS |
| Amgen Inc. | $14.20 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111527044 | CMS |
| Amgen Inc. | $17.79 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117200612 | CMS |
| Amgen Inc. | $18.66 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111527046 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.22 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104628072 | CMS |
| Dexcom, Inc. | $23.64 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153278773 | CMS |
| iRhythm Technologies, Inc. | $15.00 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154050078 | CMS |
| Lilly USA, LLC | $14.47 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136028128 | CMS |
| Lilly USA, LLC | $17.25 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136033566 | CMS |
| Lilly USA, LLC | $18.68 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136037195 | CMS |
| Novartis Pharmaceuticals Corporation | $13.07 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086773451 | CMS |
| Novo Nordisk Inc | $14.20 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096846198 | CMS |
| Novo Nordisk Inc | $16.99 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097158092 | CMS |
| Novo Nordisk Inc | $18.32 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096752113 | CMS |
| Novo Nordisk Inc | $16.21 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096584818 | CMS |
| Novo Nordisk Inc | $14.56 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096911726 | CMS |
| Novo Nordisk Inc | $13.24 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096641001 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.